-
PRLISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8..
LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangit..
2024.04.03 -
PRLISCure Biosciences Announces FDA Clearance of IND Application to Init..
FEB 29 2024 14:00 GMT- Represents first ever live biotherapeutic product to receive IND clearance for PSC- Phase 2 clini..
2024.03.04 -
PRCelltrion and LISCure Biosciences announce strategic collaboration to ..
■ Co-research and co-development of novel microbiome therapeutics■Discovery of new candidates to meet high unmet medica..
2023.02.21 -
PRLISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD)..
First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseasesSEOUL, South Korea,..
2022.12.09 -
PRLISCure Biosciences Announces Oral Presentation of New Drug Candidate ..
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been co..
2022.10.28 -
PRLISCure Biosciences Announces Research Collaboration with The Scripps ..
SEOUL, South Korea,Feb. 3, 2022/PRNewswire/ --LISCure Biosciences ("LISCure") announced that it had reached an..
2022.02.03 -
PRLISCure Biosciences announces research collaboration with Mayo Clinic ..
SEOUL, South Korea,Jan. 6, 2022/PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focused on microbial-based th..
2022.01.06 -
PRLISCure Biosciences received clinical approval for two microbiome prog..
SEOUL, South Korea,Sept. 30, 2021/PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it has receive..
2021.10.01 -
PRLISCure Biosciences Announces Know-How License Agreement and Stock Pur..
SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered into a kno..
2021.08.01